At a glance
ClinicalIndex Comparison RecordN/ACompleted· 109 enrolled
Drug / intervention
AirSeal System +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Comparative Study of CO2 Exchange Patterns Between Valve-free Trocar (AirSeal®) Versus Standard Trocar (Endopath®) During Robotic Prostatectomies
In Brief
A clinical study evaluating AirSeal System and Standard Endopath for Prostate Cancer and Pneumoperitoneum. Completed, enrolled 109 participants across 1 site.
Detailed Summary
The AirSeal® System will allow for lower carbon dioxide (CO2) absorption rates than the standard Endopath System.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer, Pneumoperitoneum
CountriesUnited States
CollaboratorsSurgiQuest, Inc.
Timeline
N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedApr 2014
Enrollment StartAug 2016
Primary CompletionMay 2018
Study CompletionJul 2019
TodayJul 2026
First PostedApr 15, 2014
Enrollment StartAug 1, 2016
Primary CompletionMay 3, 2018
Study CompletionJul 15, 2019
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 12.2 years ago
Interventions
AirSeal Systemdevice
To analyze the results of patients randomized to either the AirSeal system or Standard Endopath trocar.
Standard Endopathdevice
This group receives the Standard Endopath Trocar for intraoperative insufflation.